tbuckley/cabot-search huggingface dataset:
Single versus multiple port laparoscopic left lateral sectionectomy for hepatocellular carcinoma: A retrospective comparative study
Authors: Jun-Cheng Wang, Yangxun Pan, Jinbin Chen, Dandan Hu, Yiminjiang Tuoheti, Zhongguo Zhou, Li Xu, Jiancong Chen, Minshan Chen, Yaojun Zhang
Journal: International Journal of Surgery (2020)

Single port laparoscopic hepatectomy has been applied in some surgeries. We aimed to describe our experience with single port laparoscopic left lateral sectionectomy (SPLS) and to compare the safety and feasibility of this technique with those of conventional multi-port laparoscopic left lateral sectionectomy (MPLS) in the treatment of hepatocellular carcinoma (HCC).A total of 72 consecutive patients who underwent SPLS (n = 33) and MPLS (n = 39) for HCC were enrolled. The peri-operative parameters of safety and feasibility, as well as the short-term oncological outcomes were compared.The length of postoperative hospital stay (LOS) was significantly shorter in the SPLS group than in the MPLS group (4.12 vs. 4.59 days, P = 0.043). No significant difference between the two groups was found in the operation time (104.58 vs. 95.69 min in the SPLS group and MPLS group respectively, P = 0.353) or the amount of blood loss (62.73 vs. 68.46 ml, P = 0.595). The 1-year recurrence-free survival rate was 77.9% in the SPLS group and 70.7% in the MPLS group (P = 0.82). Subgroup analysis showed that for patients without cirrhosis, the LOS was shorter in the SPLS group than in the MPLS group (P = 0.033), while for patients with cirrhosis, the LOS was not significantly different between the two groups (P = 0.201), although it was shorter in the SPLS group.SPLS was a feasible and safe surgical approach for the treatment of HCC on left lateral section.
Use of locoregional treatment to improve survival in de novo stage IV breast cancer patients with luminal-like and HER2-rich subtypes.
Authors: Pengyu Chen, Skye H Hong-Chun Cheng
Journal: Journal of Clinical Oncology (2013)

e12003 Background: Breast cancer has three major subtypes, including luminal-like (hormone receptor positive, no HER2 overexpression), HER2-rich (HER2 overexpression), and triple negative (hormone receptor negative and no HER2 overexpression). This study is to analyze the prognosis in each subtype of stage IV breast cancer patients. Methods: We reviewed 246 patients with de novo stage IV breast cancer treated at our hospital between 1990 and 2009. Multivariable Cox analysis was used to determine the survival associated the subtypes and clinicopathologic factors. Results: Patients with luminal-like subtype are mostly premonopausal (66.9%, P=0.0002), with abnormal CA 15-3 level at initial diagnosis (58.7%, P=0.01), with higher rate of bone mets (78.1%, P=0.02), and less rate of liver mets (23.1%, P&lt;0.0001). Patients with HER2-rich and triple negative had higher rate of nuclear grade III of primary breast tumor, up to 35% and 40%, respectively (P=0.01). There is no difference in the systemic chemotherapy (82.2~95%, P=0.09) and locoregional treatment (40.0~51.2%, P=0.23) among three groups. The median overall survival of 246 patients was 23.1 months. The median overall survival in patients with luminal-like, HER2-rich, and triple negative subtype were 39.6, 17.9, and 13.3 months, respectively (P&lt;0.0001). In multivariate analysis, hormone receptor and HER2 status were significant independent factors associated with survival (P&lt;0.0001). Other significant factors associated with survival included liver mets (Hazard Ratio 2.3, P&lt;0.0001), lung mets (Hazard Ratio 1.7, P=0.0004), and brain mets (Hazard Ratio 1.5, P=0.03). In subgroup analysis, locoregional treatment to primary breast tumor had significant survival benefit in patients with luminal-like (P=0.0001) and HER2-rich(P=0.0012) subtype. In triple negative subtype, local treatment did not improve outcome (P=0.9575). Conclusions: Hormone receptors and HER2 status are the most important factors affecting survival for these patients. Locoregional treatment to primary breast tumor may provide better outcome, especially those with luminal-like or HER2-rich subtype.
Impact of computerized provider order entry on medication errors in chemotherapy administration.
Authors: Patricia A DeMoor, Lyudmila Bazhenova
Journal: Journal of Clinical Oncology (2012)

e16535 Background: Computerized provider order entry (CPOE) reduces medication errors (ME) in ambulatory prescriber and hospital settings. We conducted a study to assess the effect of CPOE on ME in an outpatient NCI designated academic infusion center (IC). Methods: Both actual and prevented ME were reported by clinical staff as part of IC Standard Operating Procedure using the electronic Quality Variance Reporting (eQVR, Incident Reporting 2.0, University of California) system. Reported ME from 10/2007 to 03/2011 were reviewed by 2 investigators and classified into categories by consensus: wrong medication given (WM), medication missed (MM), wrong timing/rate (T/R), wrong dose (WD), unmet chemotherapy parameters (UP) and other (O). Classifications were further categorized by preventable or facilitated by CPOE. We compared ME 18 mo. pre and post implementation. The 6 month go live period was reviewed separately to examine ME related to a learning curve (LC). Results: 40,366 patients were seen pre-implementation, 47,460 post, and 14,343 during go live. The total ME per pt was similar pre and post (see table). There were dramatic rate differences in WM and MM, but no effect on T/R, WD, UP. In the pre period 66% of ME were felt preventable by CPOE. In turn 35% of ME were facilitated by CPOE. Preventability rates differed between categories. During go live 100% of CPOE facilitated ME were related to user and designer LC. Post implementation 58% of CPOE facilitated ME were still accounted by LC with the rest felt related to the complexity of CPOE. Conclusions: ME are rare in our outpatient oncology IC. CPOE did not change the total number of ME but significantly decreased the rate of WM. Complexities of CPOE resulted in increased MM. LC related errors still occur 24 mo. after implementation of CPOE and require constant monitoring and education. CPOE increased the rate of serious ME felt due to the change in workflow and adding an extra layer of complexity. Human errors cannot be fixed with CPOE and generally encompassed the ME in T/R, WD, and UP classifications. [Table: see text]
The influence of human papilloma virus (HPV) infection on the outcome of subjects with anal squamous cell carcinoma.
Authors: Anu Batra, Leah J Hennings, Jennifer D James, Eric R Siegel, Rangaswamy Govindarajan
Journal: Journal of Clinical Oncology (2013)

e15152 Background: HPV infection is a risk factor for the development of anal cancer. P16 expression correlates highly with HPV infection. The influence of HPV infection on the outcome of these subjects has not been well defined. To evaluate the influence of HPV infection on prognosis of subjects with anal squamous cell cancer, a retrospective analysis was conducted. Methods: Subjects with anal squamous cell cancer diagnosed at the University of Arkansas for Medical Sciences between 1992 and 2010, were identified from the tumor registry. The charts were reviewed to confirm the diagnosis, stage, treatment and outcome of the subjects. Paraffin tissue blocks of the subjects were stained for p16 expression using the immunoperoxidase method using mouse monoclonal antibody (Clone E6H4) and CINTek Histology VKit. Slides were scanned to digital file (Aperio CS, Aperio, Vista, CA). Neoplastic regions were analyzed using a color deconvolution algorithm (Aperio). Based on the percentage of pixels with weak, moderate, strong, and negative staining, each slide was given a score between 0-300. Score of 150 and above was designated as positive. P16 positive and negative groups were compared for differences in recurrence-free survival (RFS) and overall survival (OS) via log-rank test. Results: There were 19 deaths observed among 33 study-eligible subjects during 103.2 person-years of follow-up. The median age (quartiles) was 53 (45-61) years. Males were 55%; Caucasians were 94%. All subjects were treated with chemotherapy and radiation. 26 subjects were p16 positive and 7 were p16 negative. The median RFS was 2.99 years for the p16-positive group vs. 1.90 years for the p16-negative group (p = 0.32). The median OS was 3.14 years for p16-positives vs. 2.00 years for p16-negatives, (p = 0.52). Conclusions: 78% of the patients with anal squamous cell cancer in our study were p16-positive. The RFS and OS tended to be longer for patients with p16-positive cancer, but the lack of statistical significance might be explained by the small number of p16-negative subjects. A larger study needs to be conducted to further evaluate the difference. [Table: see text]
ASSOCIATION BETWEEN ABNORMAL BIOMARKER RELEASE AND MYOCARDIAL EDEMA ASSESSED BY MAGNETIC RESONANCE IMAGING AFTER UNCOMPLICATED REVASCULARIZATION PROCEDURES
Authors: Fernando Faglioni Ribas, Whady Hueb, Paulo Rezende, Carlos Rochitte, Cesar Nomura, Thamara Morais, Eduardo Gomes Lima, Gustavo Boros, Felipe Pereira Camara Carvalho, Matheus Ribeiro, Jaime Linhares Filho, Anderson Roberto Dallazen, Rafael Silva, Mauricio Mocha, Carlos Serrano, Jose Ramires, Roberto Kalil-Filho
Journal: Journal of the American College of Cardiology (2020)
CORRELATION OF CORONARY INFLAMMATORY MARKERS LIKE HIGH SENSITIVE C REACTIVE PROTEIN, TUMOR NECROSIS FACTOR, INTERLEUKIN 6 WITH PERIVASCULARFAT ATTENUATION INDEX TO STRATIFY THE CARDIAC RISK ASSOCIATED WITH THE PRESENCE OF ADVERSE PLAQUE MORPHOLOGY
Authors: Naresh Sen, Sonal Tanwar, Naresh Sen
Journal: Journal of the American College of Cardiology (2020)
Analysis of NRAS mutation as poor prognostic indicator and predictor of resistance to anti-EGFR monoclonal antibodies (anti-EGFRs) in metastatic colorectal cancer (mCRC) patients (pts).
Authors: Marta Schirripa, Fotios Loupakis, Chiara Cremolini, Manfredi Morvillo, Francesca Bergamo, Federica Zoratto, Lisa Salvatore, Carlotta Antoniotti, Federica Marmorino, Elisa Sensi, Cristiana Lupi, Gabriella Fontanini, Veronica De Gregorio, Riccardo Giannini, Fulvio Basolo, Gianluca Masi, Alfredo Falcone
Journal: Journal of Clinical Oncology (2013)

3613 Background: NRAS belongs to RAS family. NRAS mutations are mutually exclusive with KRAS and BRAF mutations and contribute to the activation of Ras/Raf/MAPK pathway. Previous experiences evaluated the prognostic/predictive role of NRAS mutations suggesting a poorer prognosis and resistance to anti-EGFRs for NRASmutant (mut) mCRC pts. The aim of the present study was to confirm such preliminary findings in a large cohort of mCRC pts. Methods: Data on KRAS (codons 12, 13 and 61) and BRAF-V600E mutational status of mCRC pts referred to our pathology from '09 to '12 were collected. NRAS mutational status (codons 12, 13 and 61) was evaluated in KRAS and BRAF wt pts. OS was calculated from date of diagnosis of metastatic disease. Data on response and PFS according to RECIST were collected for NRASmut irinotecan-refractory pts treated with anti-EGFRs +/- irinotecan. Results: 774 mCRC pts were included. KRAS/BRAF mutations were found in 384 (50%)/69 (9%) cases. NRAS was mut in 47 (15%) out of 318 KRAS and BRAF wt pts. NRAS mut pts had significantly shorter OS in comparison to KRAS-BRAF-NRAS wt pts (HR=0.60 [0.29-0.99] p=0.045). BRAF mut pts had significantly worse OS in comparison to NRAS mut pts (HR=1.75 [1.073-2.87] p=0.03). No difference was observed between NRAS mut and KRAS mut pts (HR=0.86 [0.51-1.43] p=0.61). 18 pts out of 47 NRAS mut pts received anti-EGFRs in advanced lines. 8 pts (7 cetuximab-based, 1 panitumumab monotherapy) were evaluable according to RECIST criteria and therefore eligible for the present analysis. None of them responded and only 1 SD was observed. Pooling our results with available data on anti-EGFRs’ activity in NRASmut pts in advanced lines of treatment (De Roock, 2010; Peeters, 2013; Andrè, 2012), only 1 response is described out of 35 treated pts (2,9%). Conclusions: Our data demonstrate that NRAS mutations have a relevant incidence in KRAS and BRAF wt mCRC pts. Present results are consistent with previous experiences and confirm that NRAS mutations affect prognosis of mCRC patients and predict lack of response to anti-EGFRs. Further insights into NRAS mut mCRC biology and prospective validation are warranted.
Patterns of relapse after concurrent temozolomide and dose-escalated intensity-modulated radiation therapy (IMRT) in newly diagnosed glioblastoma (GBM).
Authors: Corey Speers, Larry Junck, Jason Heth, Yue Cao, Theodore Steven Lawrence, Christina Tsien
Journal: Journal of Clinical Oncology (2013)

2052 Background: We hypothesized that IMRT would permit us to safely escalate the dose of radiation with concurrent temozolomide substantially above the current standard of 60 Gy and that this increased dose would more adequately control local disease leading to an alteration in the patterns of relapse in patients with GBM. Methods: Between 2003 and 2012 a total of 69 patients were treated with dose-escalated IMRT with concurrent temozolomide. 39 patients were initially treated in a combined phase I/II trial with IMRT doses of 66 to 81 Gy over 6 weeks with concurrent daily temozolomide (75 mg/m2) followed by adjuvant cyclic temozolomide (200 mg/m2 d1-5 q28d for 6 or more cycles). Subsequently, 30 additional patients were treated to 66-72 Gy based on the reported efficacy and safety of the initial phase I/II study. Results: All 69 patients were assessed to evaluate the effect of dose escalation on late toxicity and patterns of progression. Median RT dose was 72 Gy and median overall survival was 19.0 months. Late CNS grade III toxicity was observed at 78 (2 of 7 patients) and 81 Gy (1 of 9 patients). 0 of 53 patients receiving 75 or less Gy developed necrosis. 64% (44/69) of patients had progression of their disease after dose-escalated chemoradiotherapy. The patterns of progression differ, however, from previous studies which identify in-field relapse of 72-80% with standard dose radiation (Brandes AA, Tosoni A, Franceschi E, et al: J Clin Oncol. 27:1275-9, 2009). In this cohort, 41% (18/44) of patients developed marginal or distant relapse compared to 59% (26/44) who developed local, in-field relapse. Conclusions: Patients with GBM can safely receive standard temozolomide with up to 75 Gy in 30 fractions, delivered using IMRT. Dose-escalated chemoradiotherapy improves local control and leads to an increased percentage of patients progressing distally, highlighting the need for improved tumor targeting with newer imaging modalities to identify the initial extent of tumor involvement as well as the need for more effective systemic treatment. I/II study.
Effect of targeting of syndecan-1 by microRNA miR-10b on breast cancer cell motility and invasiveness via a rho-GTPase- and E-cadherin-dependent mechanism.
Authors: Ludwig Kiesel, Sherif Abdelaziz Ibrahim, George W Yip, Martin Gotte
Journal: Journal of Clinical Oncology (2012)

e21041 Background: microRNAs are small endogenous non-coding RNAs, which posttranscriptionally regulate gene expression. In breast cancer, overexpression of the transmembrane heparan sulfate proteoglycan syndecan-1, a predicted target of the oncomiR miR-10b, correlates with poor clinical outcome. Here, we investigatet the potential functional relationship of miR-10b and syndecan-1 in an in vitro study. Methods: MDA-MB-231 and MCF-7 breast cancer cells were transiently transfected with pre-miR-10b, syndecan-1 siRNA or control reagents, respectively. Altered cell behaviour was monitored by proliferation, migration and invasion chamber assays, and time-lapse video microscopy. Results: miR-10b overexpression induced posttranscriptional downregulation of syndecan-1, as demonstrated by qPCR, flow cytometry, and 3’UTR luciferase assays, resulting in increased cancer cell migration and matrigel invasiveness. Syndecan-1 silencing generated a copy of this phenotype. Adhesion to fibronectin and laminin and basal cell proliferation were increased. Syndecan-1 co-immunoprecipitated with focal adhesion kinase, which showed increased activation upon syndecan-1 depletion. Affymetrix screening and confirmatory qPCR and Western blotting analysis of syndecan-1 deficient cells revealed upregulation of ATF-2, COX- 2, cadherin-11, vinculin, ACTG2, MYL9, transgelin-1, RhoA/C, MMP2 and heparanase, and downregulation of AML1/RUNX1, E-cadherin, CLDN1, p21WAF/CIP, Cdk6, TLR-4, PAI1/2, Collagen1alpha1, JHDM1D, Mpp4, MMP9, matrilin-2 and ANXA3/A10. Video microscopy demonstrated massively increased Rho kinase-dependent motility of syndecan-1-depleted cells, which displayed increased filopodia formation. Conclusions: We conclude that syndecan-1 is a novel target of the oncomiR miR-10b. Rho-GTPase dependent modulation of cytoskeletal function and downregulation of E-cadherin expression are identified as relevant effectors of the miR-10b-syndecan-1 axis, which emerges as a promising target for the development of new therapeutic approaches for breast cancer.
LEFT ATRIAL PHASIC VOLUMES AND GLOBAL LONGITUDINAL STRAIN HAVE PROGNOSTIC VALUE IN PATIENTS UNDERGOING TRANSARTERIAL VALVE IMPLANTATION FOR SEVERE AORTIC STENOSIS
Authors: Jonathan Weber, Simcha Pollack, Florentina Petillo, Kristine Bond, Michael Passick, Joseph Flanagan, Eddy Barasch
Journal: Journal of the American College of Cardiology (2020)
PROSTHESIS-PATIENT MISMATCH BETWEEN TRANSCATHETER HEART VALVES IN TRANSCATHETER AORTIC VALVE REPLACEMENT
Authors: Aditya Sengupta, Syed Zaid, Jason Storch, Eisha Gupta, Sameer Hirji, Hasan Ahmad, Asaad Khan, Cenap Undemir, Omar Ali, Jeffrey Skiles, Joshua Goldberg, Steven Lansman, Jason Kovacic, George D. Dangas, Samin K. Sharma, Annapoorna Subhash Kini, Basel Ramlawi, Pinak Shah, Tsuyoshi Kaneko, Gilbert Tang
Journal: Journal of the American College of Cardiology (2020)
The impact of exercise training on fatigue in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis
Authors: Mara Paneroni, Michele Vitacca, Massimo Venturelli, Carla Simonelli, Laura Bertacchini, Simonetta Scalvini, Federico Schena, Nicolino Ambrosino
Journal: Pulmonology (2020)

Fatigue can be divided in perceived fatigue, the feeling of exhaustion or lack of energy, and performance fatigue, the reduction in muscle force/activation during a given task. This meta-analysis evaluates the impact of exercise training on fatigue, compared with normal care in patients with COPD. We searched randomised controlled trials on MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials and CINAHL databases from their inception to December, 31st 2019 using the terms COPD, Fatigue, Fatigability, Muscle activation, Muscle endurance, Muscle Performance, Voluntary Activation, Motoneuron excitability, Force Development, Exercise, AND Rehabilitation. We evaluated 494 potential articles. Sixteen, all evaluating perceived fatigability, satisfied the inclusion criteria and were included. Twelve studies (463 patients) assessed fatigue by the Chronic Respiratory Questionnaire showing that intervention improved significantly more than the control group [SMD 0.708; 95% CI 0.510, 0.907; p < 0.001; I² = 34.3%; p = 0.116]. Two studies (68 patients) using the Fatigue Impact Scale, did not find any significant differences between groups [SMD −0.922; 95%CI −2.258, 0.413; p = 0.176; I² = 83.9%; p = 0.013]. Two studies (82 patients) assessed perceived fatigue by the Fatigue Severity Scale: the intervention improved significantly more than the control group [SMD −2.282; 95%CI −2.870, −1.699; p < 0.001; I² = 64.6%, p = 0.093]. No study evaluating performance fatigue was found. This study provided low-quality evidence of a positive impact of different exercise training programs on perceived fatigue in patients with COPD. Further studies are needed to assess the effects of exercise training on fatigue and to test tailored programs.
Effect of osteoporosis in postmenopausal breast cancer patients randomized to adjuvant exemestane or anastrozole: NCIC CTG MA.27.
Authors: Lois E. Shepherd, Judy-Anne W. Chapman, Suhail M. Ali, Liting Zhu, Kim Leitzel, Paul Edward Goss, Allan Lipton
Journal: Journal of Clinical Oncology (2012)

501 Background: NCIC CTG MA.27 compared adjuvant steroidal [exemestane (E)] and non-steroidal [anastrozole (A)] aromatase inhibitors (AIs) and showed neither to be superior in breast cancer outcomes. AIs are known to increase the risk of osteoporosis. We examined the effects of baseline or subsequent self reported osteoporosis on disease outcomes. Methods: MA.27 enrolled 7,576 women. Event free survival (EFS) was the primary endpoint. Distant disease-free-survival (DDFS) was a secondary outcome. MA.27 permitted bisphosphonates to prevent or treat osteopenia or osteoporosis unless prohibited by enrollment to one of two cohorts in a bone substudy. Osteoporosis was considered present for this analysis if reported at baseline or prior to relapse or breast cancer death. Multivariate stratified Cox regression was used to examine the effects of trial therapy, osteoporosis, baseline patient and tumour characteristics on EFS; DDFS; bone only relapse; bone concurrent with other relapse; and non-bone recurrence. Bone marrow recurrence (N=8) was excluded. Results: Osteoporosis was reported at baseline by 654 of 7576 (8.6%) women, and prior to relapse by an additional 661 women. EFS events occurred in 693/7576 (9.15%). Osteoporosis was significantly associated with better EFS [HR 0.81 (95% CI 0.66-0.99), p=0.04] with no difference in multivariate HR of E vs A: 1.02, 95% CI 0.88-1.19, p=0.77. Women experienced 313 (4.1%) DDFS events. Osteoporosis was associated with better DDFS [HR 0.71 (95% CI 0.51-0.98), p=0.04], adjusted HR of E to A: 0.94 (95% CI of 0.75-1.17), p=0.56. Both EFS and DDFS interactions of osteoporosis with trial therapy were not significant (p&gt;0.05). Osteoporosis was not significantly associated with the site of relapse. Conclusions: Osteoporosis had a significant prognostic association with improved EFS and DDFS in women treated with AIs. We plan to investigate the use of bisphosphonates, raloxifene treatment prior to randomization, and markers of bone resorption with outcome.